Clinical Centre, Department of Otorhinolaryngology and Head and Neck Surgery, University of Pecs, Munkacsy M Str 2, Pecs, H-7621, Hungary.
Tolna County Balassa Janos Hospital, Beri Balogh Adam Str 5-7, Szekszard, H-7100, Hungary.
Pathol Oncol Res. 2020 Oct;26(4):2801-2807. doi: 10.1007/s12253-020-00849-5. Epub 2020 Jun 21.
Squamous cell carcinoma (SCC) of the head and neck region is the sixth most frequent malignancy with high mortality rate. Due to its poor prognosis it is considered a growing public health problem worldwide inspite of existing treatment modalities. Thus, early diagnosis of new diseases and recurrences is emerging on one hand, but on the other hand troublesome in the lack of reliable tumor markers in this field. The rapid development of proteomics has opened new perspectives in tumor marker discovery. Liquid chromatography/mass spectrometry (LC/MS) as the gold standard in proteomics enables the semi-quantitative analysis of proteins within various tissues. Abundance differences between tumor and normal tissue also can be interpreted as tumor specific changes. The aim of this study was to identify potential tumor markers of laryngeal/hypopharyngeal SCC by revealing abundance changes between cancerous and the surrounding phenotypically healthy tissue. After separating the phenotypically cancerous and healthy parts of formalin-fixed paraffin-embedded tissues, each sample underwent protein recovery process and tryptic digestion for label-free semi-quantitative LC/MS analysis. Eight proteins showed significantly higher abundance in tumor including tenascin, transmembrane emp24 domain-containing protein 2, cytoplasmic dynein light chain 1, coactosin-like protein, small proline-rich protein 2D, nucleolin, U5 small nuclear RNP 200-kDa helicase and fatty aldehyde dehydrogenase. Desmoglein-1 and keratin type I cytoskeletal 9 were down-regulated in tumor. Using Ingenuity Pathway Analysis we mapped the signaling pathways these proteins play role in regarding other tumors. Based on these findings these proteins may serve as promising biomarkers in the fight against laryngeal/hypopharyngeal SCCs.
头颈部鳞状细胞癌(SCC)是第六大常见恶性肿瘤,死亡率高。尽管存在现有治疗方法,但由于预后不良,它被认为是全球日益严重的公共卫生问题。因此,一方面,新疾病和复发的早期诊断成为一个关注点,另一方面,由于该领域缺乏可靠的肿瘤标志物,这也很麻烦。蛋白质组学的快速发展为肿瘤标志物的发现开辟了新的视角。作为蛋白质组学的金标准,液相色谱/质谱(LC/MS)能够对半定量分析各种组织中的蛋白质。肿瘤组织与正常组织之间的丰度差异也可以解释为肿瘤特异性变化。本研究的目的是通过揭示癌症组织与周围表型健康组织之间的丰度变化,来鉴定喉/下咽鳞状细胞癌的潜在肿瘤标志物。在分离出表型癌变和正常组织后,每个样本都经历了蛋白质回收过程和胰酶消化,用于无标记半定量 LC/MS 分析。有 8 种蛋白质在肿瘤中表现出明显更高的丰度,包括 tenascin、跨膜 emp24 结构域包含蛋白 2、细胞质动力蛋白轻链 1、协同蛋白样蛋白、小脯氨酸富含蛋白 2D、核仁素、U5 小核 RNA 200kDa 解旋酶和脂肪醛脱氢酶。桥粒蛋白 1 和角蛋白类型 I 细胞骨架 9 在肿瘤中下调。使用 Ingenuity Pathway Analysis,我们绘制了这些蛋白质在其他肿瘤中发挥作用的信号通路。基于这些发现,这些蛋白质可能成为对抗喉/下咽鳞状细胞癌的有前途的生物标志物。